Affiliation: Johns Hopkins University
- Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label studyLaura Marsh
Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
Mov Disord 24:277-82. 2009..Adverse effects included sleep and gastrointestinal disturbances and hypomania. Atomoxetine is tolerable in PD and may benefit clinical manifestations of ED, warranting further study in controlled trials...
- Provisional diagnostic criteria for depression in Parkinson's disease: report of an NINDS/NIMH Work GroupLaura Marsh
Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
Mov Disord 21:148-58. 2006..The proposed diagnostic criteria are provisional and intended to be defined further and validated but provide a common starting point for clinical research in PD-associated depression...
- Psychiatric comorbidities in patients with Parkinson disease and psychosisL Marsh
Department of Psychiatry and Behavioral Sciences, Morris K Udall Parkinson s Disease Research Center of Excellence at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
Neurology 63:293-300. 2004..To determine the prevalence and impact of comorbid psychiatric disturbances in Parkinson disease (PD) patients with psychosis...
- Neuropsychiatric aspects of Parkinson's disease: recent advancesLaura Marsh
Division of Psychiatric Neuroimaging, Geriatric and Neuropsychiatry Programs, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, 600 North Wolfe Street, Phipps 300 C, Baltimore, MD 21287, USA
Curr Psychiatry Rep 5:68-76. 2003..This review addresses the diagnosis and treatment of the most common psychiatric disorders in PD, and provides an update of related clinical research, including studies on neurosurgical treatments...
- Psychiatric complications in patients with epilepsy: a reviewLaura Marsh
Neuropsychiatry and Memory Group, Department of Psychiatry and Behavioral Sciences, School of Medicine, Johns Hopkins University, 600 N Wolfe Street, Baltimore, MD 21287, USA
Epilepsy Res 49:11-33. 2002..Pharmacological and non-pharmacological therapies are reviewed. A final section discusses potential interactions between antiepileptic and psychiatric medications...
- Structural brain abnormalities in patients with schizophrenia, epilepsy, and epilepsy with chronic interictal psychosisL Marsh
Department of Psychiatry and Behavioral Sciences, Stanford University Medical School, Stanford, CA, USA
Psychiatry Res 108:1-15. 2001..Structural brain abnormalities in E+PSY are not restricted to the left temporal lobe. The confluence of cortical gray matter deficits in E+PSY and SCZ suggests salience to chronic psychosis...
- N1 and P300 abnormalities in patients with schizophrenia, epilepsy, and epilepsy with schizophrenialike featuresJ M Ford
Department of Psychiatry and Behavioral Science, Stanford University School of Medicine, Stanford, California 94304, USA
Biol Psychiatry 49:848-60. 2001..N1 amplitude reduction appears to be specific to schizophrenia, suggesting its sensitivity to the distinct etiology of schizophrenia...
- A profile of cortical gray matter volume deficits characteristic of schizophreniaE V Sullivan
Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, CA 94305 5717, USA
Cereb Cortex 8:117-24. 1998..The overlapping patterns of cortical gray matter deficits in the two groups provide evidence for generality of this pattern of regional brain volume abnormalities in schizophrenia...
- Neuropsychiatric aspects of Parkinson's diseaseL Marsh
Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
Psychosomatics 41:15-23. 2000..This review describes the various motor and nonmotor features of PD and focuses on the differential diagnosis of affective disorders in PD and their treatment...
- Olanzapine for the treatment of psychosis in patients with Parkinson's disease and dementiaL Marsh
Morris K Udall Parkinson's Disease Research Center of Excellence at Johns Hopkins, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD 21287, USA
Psychosomatics 42:477-81. 2001..There was no improvement in psychotic symptoms, and functional abilities declined significantly. Olanzapine appears to be poorly tolerated in patients with Parkinson's disease, psychotic symptoms, and dementia...
- Differential impairment of spatial location memory in Huntington's diseaseJ Brandt
Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21287 7218, USA
J Neurol Neurosurg Psychiatry 76:1516-9. 2005..To determine whether a differential impairment of spatial memory exists in Huntington's disease (HD)...
- Psychopathology in patients with degenerative cerebellar diseases: a comparison to Huntington's diseaseIracema Leroi
Program in Cellular and Molecular Medicine, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
Am J Psychiatry 159:1306-14. 2002..This study estimated the psychiatric morbidity of patients with degenerative cerebellar diseases...
- Morphometry of the human substantia nigra in ageing and Parkinson's diseaseGay Rudow
Neuropathology, Johns Hopkins School of Medicine, Ross Research Building 555, 720 Rutland Avenue, Baltimore, MD 21205, USA
Acta Neuropathol 115:461-70. 2008..Presumably, this compensatory mechanism breaks down or is overwhelmed by the pathological events of PD leading to the onset of the characteristic motor disturbances...
- Scales to assess psychosis in Parkinson's disease: Critique and recommendationsHubert H Fernandez
Department of Neurology, McKnight Brain Institute University of Florida, Gainesville, Florida 32611, USA
Mov Disord 23:484-500. 2008..The CGIS is suggested as a secondary outcome scale to measure change and response to treatment over time...
- Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work groupBernard Ravina
Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, NY 14620, USA
Mov Disord 22:1061-8. 2007..These criteria require validation and may be refined, but form a starting point for studies of the epidemiology and pathophysiology of PDPsy, and are a potential indication for therapy development...
- Fatigue in Parkinson's disease: a reviewJoseph H Friedman
NeuroHealth, Warwick, Rhode Island 02886, USA
Mov Disord 22:297-308. 2007..This article reviews what is known about the symptom, putting it into the context of fatigue in other disorders, and outlines a program for developing better understanding and therapy...
- Non-dopaminergic treatment of cognitive impairment and dementia in Parkinson's disease: a reviewIracema Leroi
Division of Psychiatry, University of Manchester, Manchester, United Kingdom
J Neurol Sci 248:104-14. 2006..To review the clinical management of cognitive impairment and dementia related to Parkinson's disease (PD), with emphasis on pharmacologic intervention strategies such as cholinesterase inhibitors...
- Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's diseaseIracema Leroi
Department of Psychiatry, North Manchester General Hospital, Manchester, UK
Int J Geriatr Psychiatry 19:1-8. 2004..To evaluate the efficacy and safety of donepezil, an acetylcholinesterase inhibitor, as a treatment for cognitive impairment and dementia in patients with Parkinson' s disease (PD)...
- Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseasesOlga Pletnikova
Department of Pathology Neuropathology, Johns Hopkins University School of Medicine, Ross Building 558, Baltimore, MD 21205, USA
Neurobiol Aging 26:1183-92. 2005..This suggests that Abeta enhances the development of cortical alpha-synuclein lesions in cases of PD...
- Ten most commonly asked questions about the psychiatric aspects of Parkinson's diseaseStephen G Reich
Department of Neurology, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
Neurologist 9:50-6. 2003
- Preservation of hippocampal volume throughout adulthood in healthy men and womenEdith V Sullivan
Department of Psychiatry and Behavioral Sciences and Neuroscience Program, Stanford University School of Medicine, 401 Quarry Road, Stanford, CA 94305 5723, USA
Neurobiol Aging 26:1093-8. 2005..Absence of hippocampus age relationships endured when restricting analyses to older individuals (> or =50 years) and considering menopause and hormone replacement therapy...
- Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutationsWenxue Li
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
Proc Natl Acad Sci U S A 102:2162-7. 2005..Collectively, our results indicate that the biology behind the generation and accumulation of alpha-SynDeltaC is likely to have relevance for the initiation and the progression of alpha-Syn aggregation in vivo...
- Hippocampal volume deficits in alcoholic Korsakoff's syndromeEdith V Sullivan
Department of Psychiatry and Behavioral Sciences and Neuroscience Program, Stanford University School of Medicine, Stanford, CA 94305 5723, USA
Neurology 61:1716-9. 2003..To examine whether the amnesic syndrome of alcoholic Korsakoff's syndrome (KS) originates from pathology of the hippocampus and not solely the diencephalon...
- S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective functionKenny K K Chung
Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
Science 304:1328-31. 2004..The inhibition of parkin's ubiquitin E3 ligase activity by S-nitrosylation could contribute to the degenerative process in these disorders by impairing the ubiquitination of parkin substrates...
- Alpha-synuclein and Parkinson's disease: implications from the screening of more than 1,900 patientsDaniela Berg
Institute for Medical Genetics, University of Tubingen, Germany
Mov Disord 20:1191-4. 2005..A53T mutation. These results demonstrate that mutations in the alpha-synuclein gene are rare and suggest that other factors contribute to alpha-synuclein aggregation in the majority of PD patients...
- Methods of Optimal Depression Detection in Parkinson'sLaura Marsh; Fiscal Year: 2006....
- Methods of Optimal Depression Detection in Parkinson'sLaura Marsh; Fiscal Year: 2009....